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cancer cellsCancer stem cells (CSCs) play a key role in tumor initiation and progression. A real-time tool to
evaluate the activation of CSC-specific signaling pathways is crucial for the study of this cancer
cell subset. Here, we present a protocol to monitor, in vitro, the activation of Wnt/b-catenin
signaling pathway, which is considered a functional biomarker for colorectal CSCs (CR-CSCs).
This flow-cytometry-based protocol allows it to isolate CR-CSCs and to evaluate their cytotoxicity
upon anti-tumor treatments.Di Franco et al., STAR
Protocols 2, 100880
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Cancer stem cells (CSCs) play a key role in tumor initiation and progression.
A real-time tool to evaluate the activation of CSC-specific signaling pathways is
crucial for the study of this cancer cell subset. Here, we present a protocol to
monitor, in vitro, the activation of Wnt/b-catenin signaling pathway, which is
considered a functional biomarker for colorectal CSCs (CR-CSCs). This flow-cy-
tometry-based protocol allows it to isolate CR-CSCs and to evaluate their cyto-
toxicity upon anti-tumor treatments.
For complete details on the use and execution of this protocol, please refer to Di
Franco et al. (2021).BEFORE YOU BEGIN
Lentiviral particles preparation
Timing: 5 days
This section describes the transfection protocol of early passage HEK293 cells (15–40 passages) to
produce lentiviral particles, using 2nd generation helper plasmids.
1. HEK293 cells preparation for transfection.
a. Twenty-four hours before the transfection (i.e., Monday, at 16:00), seed 0.8–1 3 106 HEK293
cells (or 293T cells) in a 25 cm2 Corning cell culture flask (canted neck, vented cap) with 7 mL
of Eagle’s Minimum Essential Medium (EMEM), supplemented with 10% Fetal Bovine Serum
(FBS) and antibiotics/antimycotics (complete EMEM).
Note: FBS should be heat-inactivated before use by heating it for 30minutes at 56Cwith mix-
ing, to inactivate complement proteins.
b. Gently swirl the flask to avoid the formation of cell clumps in the middle of the flask.
c. Incubate at 37C, 5% CO2 for 18–24 h.STAR Protocols 2, 100880, December 17, 2021 ª 2021 The Authors.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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OPEN ACCESS ProtocolNote: Be aware that after 40 passages, HEK293 cells start changing their morphology, thus
randomly affecting the transfection efficiency.
2. HEK293 cells transfection for lentiviral particles production.
a. At the time of transfection (i.e., Tuesday, at 16:00), after 18–24 h of incubation, the HEK293
cells should have reached 70%–80% of confluence.
CRITICAL: cell confluence >80% should be avoided since it could affect the transfectionefficiency.b. Add 500 mL of Opti-MEM Medium, 12 mL of X-tremeGENE HP DNA Transfection Reagent,
2.6 mg of psPAX2 (#12260, Addgene), 1.4 mg of pMD2.G (#12259, Addgene) (second gener-
ation helper plasmids) and 4 mg of TOP-GFP.mC lentiviral vector plasmid (#35491, Addgene),
or FOP-GFP.mC (#35492, Addgene) as control (ratio X-tremeGENE HP:DNA = 3 mL : 2 mg),
into a 2 mL polypropylene tube and gently swirl the tube. The mix needs to be incubated
for at least 30 min at room temperature (23C–25C) before proceeding to next steps.
c. Before transfection, replace the cell culture medium of HEK293 cells with 7 mL of EMEM (10%
FBS) without antibiotics/antimycotics, which could interfere with the transfection efficiency.
d. Add the transfectionmix to HEK293 cells in a drop wisemanner and incubate at 37C, 5%CO2.
e. After 16–24 h of transfection (i.e., Wednesday, at 9:00), gently remove the cell culture medium
from the flask and replace it with 7 mL of complete EMEM.
3. Lentiviral particles collection and storage.
a. After 48 h from transfection (i.e., Thursday, at 16:00), gently collect the cell culture medium
from transfected HEK293 cells (first batch, to be stored at 4C for 24 h) and replace it with fresh
complete EMEM.
Note: At this time, it is highly recommended to check the expression of RFP in HEK293 cells
transfected with both TOP-GFP.mC and FOP-GFP.mC lentiviral plasmids, since this is a useful
indicator of transfection efficiency. Indeed, both the plasmids constitutively express the
mCherry RFP, but only cells transfected with TOP-GFP.mC will express GFP according to
Wnt pathway activity (due to a mutation in the TCF/LEF response elements of FOP-GFP.mC
plasmid, used as control) If RFP expression is not observed after 48 hours, be aware that
the transfection protocol may have not worked properly.
b. After 72 h from transfection (i.e., Friday, at 16:00), gently collect the second batch of cell culture
medium from transfected HEK293 cells and mix it with the first batch collected the day before.
c. Spin the collected medium at 1500 g to remove most of the cell components from the super-
natant.
d. Filter the medium with 0.45 mm filters to avoid having any residual HEK293 cell and debris in
the medium.
e. The lentiviruses are concentrated using the Lenti-X Concentrator (for detailed instructions visit
https://www.takarabio.com/documents/User%20Manual/PT4421/PT4421-2.pdf). The ob-
tained pellet is resuspended in 1/10 to 1/100th of the original volume, using Opti-MEM
Medium, and stored at 80C. One fresh lentivirus aliquot should be used for titration to
determine the multiplicity of infection (MOI), following a standard titration protocol for lenti-
viral preparations carrying a fluorescent protein marker (https://www.addgene.org/protocols/
fluorescence-titering-assay/). As an alternative, high-titer lentiviral preparations can be
obtained by performing ultracentrifugation in presence of sucrose (Brown et al., 2020).
Pause point: Proceed with the following steps of the protocol. Alternatively, lentiviral par-
ticles can be stored at 80C for long storage (up to 1 year).2 STAR Protocols 2, 100880, December 17, 2021
Figure 1. IC50 drug screening
Plate layout for MTS proliferation assay to evaluate the IC50 of anti-tumor drugs, or combinatorial treatments, at 48 h
(left panel). Heatmap of cell viability calculated from drug dose-response analysis of HCT-116 cell line treated with
Oxaliplatin, 5-FU or drug combination (FOX). Green boxes indicate IC50 values for each time point. Cells treated with
vehicle have been used as control for cell viability, calculated as [(Absorbance of cells treated with drug / Absorbance






OPEN ACCESSProtocolNote: When working with lentiviral plasmid in absence of constitutive fluorescent protein
marker expression, as TOP-GFP (cat. #35489, Addgene), or FOP-GFP as control (#35490,
Addgene), lentiviral particles titration can be performed by isolating lentiviral RNA using
the NucleoSpin RNA Virus kit (cat. #740956, Macherey-Nagel) and quantifying it using the
Quant-X One-Step qRT-PCR TB Green kit (cat. #638317, Takara).Chemotherapeutics preparation and cell treatment
Timing: 1 h
4. Preparation of 5-FU and Oxaliplatin solution.
a. Resuspend the powders in DMSO under sterile conditions to obtain a 10 mM solution. These
reconstituted drugs are stable for at least 2 years if stored at 80C.
5. In vitro treatment of colorectal cancer (CRC) cells (<50 passages).
a. Before proceeding with treatment of CRC line, perform a dose-response curve to determine
the IC50 of both single and combinatorial treatment, at different time points (Figure 1).
b. Cells are treated with Oxaliplatin 2.5 mM, and after 3 h with 5-FU 5 mM, by mimicking the clin-
ically used schedule and doses for FOX (de Gramont et al., 2000; Sorbye et al., 2004).KEY RESOURCES TABLEGENT or RESOURCE SOURCE IDENTIFIER
micals, peptides, and recombinant proteins
becco’s Phosphate Buffered Saline Euroclone Cat# ECB4004L
ine Serum Albumin Sigma-Aldrich Cat# A9418
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Trypsin-EDTA Euroclone Cat# ECB3052D
StemPro Accutase Cell Dissociation Reagent Thermo Fisher Scientific Cat# A1110501
5-FU Selleckchem Cat# S1209
Oxaliplatin Sigma-Aldrich Cat# O9512
CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS) Promega Cat# G3582
X-tremeGENE HP DNA Transfection Reagent Sigma-Aldrich Cat# 06366236001
Polybrene Sigma-Aldrich Cat# H9268
CS&T beads (FacsLyric) BD Biosciences Cat# 656505
CS&T beads (FacsMelody) BD Biosciences Cat# 661414
Accudrop beads (FacsMelody) BD Biosciences Cat# 661612
Fetal Bovine Serum (FBS) Corning Cat# 35-079-CV
EDTA Merck Cat# E6758
Trypan Blue Solution, 0.4% Thermo Fisher Scientific Cat# 15250061
Dimethyl sulfoxide (DMSO) Merck Cat# D5879
Eagle’s Minimum Essential Medium (EMEM) ATCC Cat# 30-2003
DMEM, high glucose Thermo Fisher Scientific Cat# 11965084
RPMI-1640 Medium ATCC Cat# 30-2001
McCoy’s 5a Medium Modified ATCC Cat# 30-2007
Advanced DMEM/F-12 Thermo Fisher Scientific Cat# 12634010
HEPES (1 M) Thermo Fisher Scientific Cat# 15630106
L-Glutamine (200 mM) Thermo Fisher Scientific Cat# 25030024
N-Acetyl-L-cysteine Sigma-Aldrich Cat# A7250
N-2 Supplement (100X) Thermo Fisher Scientific Cat# 17502048
Penicillin-Streptomycin 100X (10,000 U/mL) Thermo Fisher Scientific Cat# 15140122
Animal-Free Recombinant Human EGF Peprotech Cat# AF-100-15
Animal-Free Recombinant Human FGF-basic (154 a.a.) Peprotech Cat# AF-100-18B
B-27 Supplement (50X), serum free Thermo Fisher Scientific Cat# 17504044
Nicotinamide Sigma-Aldrich Cat# N3376
Gastrin I human Sigma-Aldrich Cat# G9020
OPTI-MEM Thermo Fisher Scientific Cat# 31985070
Antibiotic-Antimycotic 100X Euroclone Cat# ECM0010D
Lenti-X Concentrator TaKaRa Cat# 631232
Critical commercial assays
Brilliant Violet 421 Annexin V BioLegend Cat# 640924
Cell Staining Buffer BioLegend Cat# 420201
Annexin V Binding Buffer BioLegend Cat# 422201
CaspGLO Red Active Caspase Staining Kit BioVision Cat# #K190
CaspGLOW Red Active Caspase-3 Staining Kit BioVision Cat# #K193
NucleoSpin RNA Virus kit Macherey-Nagel Cat. #740956
Quant-X One-Step qRT-PCR TB Green kit Takara Cat. #638317
Recombinant DNA
psPAX2 Addgene Cat# 12260
pMD2.G Addgene Cat# 12259
TOP-GFP.mC (with constitutive RFP) Addgene Cat# 35491
FOP-GFP.mC (with constitutive RFP) Addgene Cat# 35492
TOP-GFP (only Wnt-driven GFP) Addgene Cat# 35489
FOP-GFP (only Wnt-driven GFP) Addgene Cat# 35490
Experimental models: Cell lines
HEK293 ATCC Cat# CRL-1573
293T ATCC Cat# CRL-3216
DLD-1 ATCC Cat# CCL-221
HT-29 ATCC Cat# HTB-38
HCT-116 ATCC Cat# CCL-247
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Software and algorithms
ELDA: Extreme Limiting Dilution Analysis Software ELDA software http://bioinf.wehi.edu.au/software/elda/




25 cm2 Rectangular Canted Neck Cell Culture Flask with Vent Cap Corning Cat# 430639
Nunc 15 mL Conical Sterile Polypropylene Centrifuge Tubes Thermo Fisher Scientific Cat# 339650
Nunc 50 mL Conical Sterile Polypropylene Centrifuge Tubes Thermo Fisher Scientific Cat# 339652
Vortex mixer VORTEXCLONE Euroclone Cat# EMXS
Medical Millex-GP Syringe Filter Unit, 0.22 mm, polyethersulfone,
33 mm, sterilized by gamma irradiation
Merck Cat# SLGPM33RS
Millex-HP Syringe Filter Unit, 0.45 mm, polyethersulfone, 33 mm,
gamma sterilized
Merck Cat# SLHP033R
1.7 mL microcentrifuge tubes Costar Cat# 3620
Costar 6-well Clear Flat Bottom Ultra-Low Attachment Multiple
Well Plates, Individually Wrapped, Sterile
Corning Cat# 3471
Nunclon Delta Surface 6-well plate Thermo Fisher Scientific Cat# 140675
Costar 24-well Clear Flat Bottom Ultra-Low Attachment Multiple
Well Plates, Individually Wrapped, Sterile
Corning Cat# 3473
Costar 24-well Clear TC-treated Multiple Well Plates, Individually
Wrapped, Sterile
Corning Cat# 3526
70 mM cell strainer Merck Cat# CLS431751
40 mM cell strainer Merck Cat# CLS431750
FACSMelody cell sorter BD Cat# 653885




OPEN ACCESSProtocolMATERIALS AND EQUIPMENTHEK293 cell culture medium
Reagent Final concentration Amount
Eagle’s Minimum Essential Medium (EMEM) 445 mL
Fetal Bovine Serum (FBS) 10% 50 mL
Antibiotic-Antimycotic 100X 1X 5 mL
 Alternatives: DMEM high glucose can be used instead of EMEM.
Store at 2 C–8 C until expiration dateDLD-1 cell culture medium
Reagent Final concentration Amount
RPMI-1640 445 mL
Fetal Bovine Serum (FBS) 10% 50 mL
Antibiotic-Antimycotic 100X 1X 5 mL
Store at 2C–8C until expiration date
HT-29 and HCT-116 cell culture medium
Reagent Final concentration Amount
McCoy’s 5a Medium Modified 445 mL
Fetal Bovine Serum (FBS) 10% 50 mL
Antibiotic-Antimycotic 100X 1X 5 mL
Store at 2C–8C until expiration date
STAR Protocols 2, 100880, December 17, 2021 5
Primary CRC organoids cell culture medium
Reagent Final concentration Amount
Advanced DMEM/F-12 457.5 mL
Hepes (1 M) 10 mM 5 mL
L-Glutamine (200 mM) 2 mM 5 mL
N-Acetyl-L-cysteine (stock solution 500 mM) 1 mM 1 mL
N-2 Supplement (100X) 1X 5 mL
Penicillin-Streptomycin 100X (10,000 U/mL) 1X 5 mL
Animal-Free Recombinant Human EGF (stock solution 50 mg/mL) 50 ng/mL 500 mL
Animal-Free Recombinant Human FGF-basic (154 a.a.) (stock solution 100 mg/mL) 100 ng/mL 500 mL
B-27 Supplement (50X), serum free 1X 10 mL
Nicotinamide (stock solution 500 mM) 10 mM 10 mL
Gastrin I human (stock solution 10 mM) 10 nM 500 mL
Store at 4C for 2 weeks.
ll
OPEN ACCESS ProtocolAs alternative strategy, EGF and basic-FGF can be freshly added only to the daily used aliquot of
medium, as to do so, the cell culture medium can be stored at 4C for 2 months.N-Acetyl-L-cysteine stock solution
Reagent Final concentration Amount
N-Acetyl-L-cysteine 500 mM 4.079 gDissolve 4.079 g of N-Acetyl-L-cysteine in 50 mL of bi-distilled sterile water in a 50 mL tube and mix
by inverting the tube (or using vortex mixer) until complete dissolution is reached. Sterilize the so-
lution by filtering it with 0.22 mm filters and aliquot in sterile (autoclavable) 1.7 mL microcentrifuge
tubes (1 mL per aliquot). Store at 20C until use. Upon reconstitution, the aliquot should be used
within six months.
ddH2O n/a 50 mLAnimal-free recombinant human EGF stock solution
Reagent Final concentration Amount
Animal-Free Recombinant Human EGF 50 mg/mL 1 mgDissolve 1 mg of Animal-Free Recombinant Human EGF in 20 mL of bi-distilled sterile water in a
50 mL tube and mix by inverting the tube (or using vortex mixer) until complete dissolution is
reached. Sterilize the solution by filtering it with 0.22 mm filters and aliquot in sterile (autoclavable)
1.7 mL microcentrifuge tubes (500 mL per aliquot). Store at20C until use. Upon reconstitution, the
aliquot should be used within six months.
ddH2O n/a 20 mLAnimal-free recombinant human FGF-basic (154 a.a.) stock solution
Reagent Final concentration Amount
Animal-Free Recombinant Human FGF-basic 100 mg/mL 1 mg
PBS 0.1% BSA n/a 10 mLDissolve 1 mg of Animal-Free Recombinant Human FGF-basic in 10 mL of sterile PBS 0.1% BSA in a
15 mL tube and mix by inverting the tube (or using vortex mixer) until complete dissolution is6 STAR Protocols 2, 100880, December 17, 2021
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OPEN ACCESSProtocolreached. Sterilize the solution by filtering it with 0.22 mm filters and aliquot in sterile (autoclavable)
1.7 mL microcentrifuge tubes (500 mL per aliquot). Store at20C until use. Upon reconstitution, the
aliquot should be used within six months.Nicotinamide stock solution
Reagent Final concentration Amount
Nicotinamide 500 mM 1.22 g
ddH O n/a 20 mLDissolve 1.22 g of Nicotinamide in 20 mL of bi-distilled sterile water in a 50 mL tube and mix by in-
verting the tube (or using vortex mixer) until complete dissolution is reached. Sterilize the solution by
filtering it with 0.22 mmfilters and aliquot in 15mL tubes (10mL per aliquot). Store at20C until use.
Upon reconstitution, the aliquot should be used within six months.
2
Gastrin I human stock solution
Reagent Final concentration Amount
Gastrin I human 10 mM 0.5 mgDissolve 0.5 mg of Gastrin I human in 23.8 mL of sterile PBS 0.1% BSA in a 50 mL tube and mix by
inverting the tube (or using vortex mixer) until complete dissolution is reached. Sterilize the solution
by filtering it with 0.22 mm filters and aliquot in sterile (autoclavable) 1.7 mL microcentrifuge tubes
(500 mL per aliquot). Store at20C until use. Upon reconstitution, the aliquot should be used within
six months.
STEP-BY-STEP METHOD DETAILS
Lentiviral transduction of cancer cells
Timing: 1 week
This protocol is aimed at the lentiviral transduction of CRC cells for the stable expression of Wnt-re-
porter gene.
1. Cell plating.
a. Collect cells at single-cell level by trypsinization (or by exposing them to Accutase).
Note: This protocol can be applied to both commercial CRC cell lines (grown in adhesion) and
primary isolated CRC cells (grown in suspension as spheroids, in ultra-low adhesion plastic)
(see Figure 2). Commonly commercially available CRC cell lines that have already been
efficiently transduced with TOP-GFP reporter plasmids include DLD-1, HT-29 and HCT-116
(Vermeulen et al., 2010).
b. Count viable cells by using Trypan blue and plate 500,000 cells in a well of a 6 well plate (adhe-
sion or ultra-low adhesion, depending on the cell type) with 2 mL of cell culture medium sup-
plemented with 8 mg/mL of Polybrene (to increase the lentiviral transduction efficiency).
CRITICAL: a prolonged exposure to polybrene could affect cell viability. Before proceed-
PBS 0.1% BSA n/a 23.8 mLing with lentiviral transduction of cells it would be useful to assess the sensitivity of the cells
to polybrene in terms of concentration and exposure time to set the best transduction
condition.STAR Protocols 2, 100880, December 17, 2021 7
Figure 2. Transduction of CRC cells with Wnt reporter construct
Fluorescence analysis of lentiviral transduction efficiency in CRC spheroids (grown in suspension) and HCT-116 CRC
cells (grown in adhesion). Scale bar, 400 mm.
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OPEN ACCESS Protocol2. Lentiviral transduction.
a. Add lentiviral particles, diluted or concentrated (MOI of 10-100), to the cells and mix gently.
Note: The optimal multiplicity of infection (MOI) for each cell line to be stable transduced
should be previously assessed to obtain the best balance between transduction efficiency
and cell viability (https://www.genecopoeia.com/resource/lentivirus-thats-my-moi-and-im-
sticking-to-it-lentivirus-moi-cell-lines/).
b. Incubate the cells at 37C, 5% CO2 for 24 h.
c. After 24 h from lentiviral transduction, put the cells back in culture in fresh cell culture medium.
3. Evaluation of lentiviral transduction.
a. After 72 h from lentiviral transduction the cells should start expressing the constitutive RFP to
be observed under a fluorescent microscope. On the other hand, the expression of GFP
should be heterogeneous, with GFP/+ cells, according to their Wnt pathway activity (Fig-
ure 2).
b. After expansion of the transduced cells, it would be useful to evaluate the transduction effi-
ciency by FACS, and eventually, enrich the cells for the RFP+ cell population (Figure 3) (see
step #7 for Brilliant Violet 421 Annexin V staining, to discriminate alive cells within TOP-GFP
cells).
Pause point: Proceed with the following steps of the protocol. Alternatively, sorted RFP+
cells can be stored in liquid nitrogen for long storage (>1 year).
Note: Typical transduction efficiency obtained using this protocol is around 75%–85%.
Cytotoxicity assay of cancer cells
Timing: 2–5 days
This section describes a protocol for determining the cytotoxicity of certain treatment on cancer cell
subpopulation with differential Wnt/b-catenin signaling based on TOP-GFP intensity. It is convention-
ally believed that CSC population, usually displaying high Wnt/ b-catenin activity, is more resistant to
therapies(Di Franco et al., 2014; Lenos et al., 2018; Vermeulen et al., 2010). With the Wnt/ b-catenin8 STAR Protocols 2, 100880, December 17, 2021
Figure 3. Evaluation and sorting of transduced CRC cells
Gating strategy for the sorting of TOP-GFP RFP+ transduced CRC spheroids.
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OPEN ACCESSProtocolsignaling reporter TOP-GFP, CSC population that exhibit high TOP-GFP signal could be specifically
screened in cytotoxicity assessment. Consequently, this protocol allows researchers to distinguishably
assess the efficiency of the treatment on cancer stem cell or more differentiated population, by FACS,
analyzing the induction of cell death (using a dye compatible with GFP and mCherry-RFP) in GFPhigh
(Wnthigh-CSCs) versus GFPlow-neg (Wntlow-neg-progenitor/differentiated) CRC cells.
4. Plate Cells.
a. Harvest RFP+-sorted TOP-GFP transduced cells by trypsinization. Mechanically open the cell
clumps by pipetting up and down with harsh pressure if cells grow in sphere or island.
CRITICAL:When pelleting the treated cells growing in adhesion cell culture conditions, forBrilliant Violet 421 Annexin V staining, make sure to collect the supernatant and pool it
together with the cell suspension after the trypsinization. The less viable cell population
would detach and float up after treatment. To avoid losing this population and bringing
in artificial bias in calculation of apoptotic percentage, floating cells should be collected
as well as attached ones. Additionally, high speed (no more than 500 g) should be used
to spin and pellet in order to ensure that the less viable cells are properly pelleted.b. Count the living cells with Trypan Blue exclusion and seed 50,000 cells per well, in a 24 well plate.
Treatment conditions could be set up in duplicate or triplicate according to experiment design.
c. Culture cells at 37C, 5%CO2 overnight (8–16 h) before treatment. Proceed to next step if cells
grow in suspension.
5. Treatment.
a. Dilute drugs and prepare solvent control.
b. Add the diluted drugs or solvent control in a dropwise manner.
c. Culture the cells for different time, according to time point setting.
Note:Before toperform a flow cytometry analysis of cell viability inWnt+ versusWnt- cells, it would
be useful to perform a dose-response curve of cancer cells to 5-FU+Oxaliplatin chemotherapy (or
any other treatment), to select the best option in terms of drug concentration and time point to
perform the analysis (or the following sorting of cells spared by the treatment) (see Figure 1).
6. Collect and pellet the treated cells.
a. Collect the supernatant in 15 mL polypropylene centrifuge tube. Label the tubes properly.
b. Trypsinize and collect the cells in the corresponding tubes. Dissociate the clumps by pipetting
up and down with harsh pressure if cells grow in sphere or island, in order to obtain a single-
cell suspension.
c. Spin at 750 g for 4 min and pellet the cells.STAR Protocols 2, 100880, December 17, 2021 9
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mined by the IC50 study), could be used as Annexin V staining negative and positive controls,
respectively.
7. Label the cells with Brilliant Violet 421 Annexin V.
a. Wash cells twice with the Staining Buffer (cat. #420201) and resuspend cells in Annexin V Bind-
ing Buffer (cat. # 422201) at a concentration of 1 3 106 cells/mL (minimum volume 100 mL)
b. Transfer 100 mL of cell suspension in a Falcon 5mL Round BottomHigh Clarity PP tube and add
5 mL of Brilliant Violet 421 Annexin V.
Note: When working with the fluorescent substrate, keep it always in the dark as it is light
sensitive.
c. Gently vortex the cells, and incubate them for 15 min at R.T., in the dark.
d. Add 400 mL of Annexin V Binding Buffer (cat. # 422201) to each tube. Analyze by flow cytometry.
8. Filter the cells through a 70 mm cell strainer, to avoid the formation of cell clumps.
Note: The use of a 40 mm cell strainer is highly recommended to avoid collection of cell dou-
blets, or when working with sticky cells, to further prevent the formation of cell clumps.
9. Measure the fluorescence of Brilliant Violet 421 Annexin V by Flow Cytometry.
a. Start up BD FACSMelody cell sorter (for detailed instruction visit: https://www.bdbiosciences.
com/content/dam/bdb/marketing-documents/BD-FACSMelody-FACSChorus-Quick-Reference-
Guide.pdf).
b. Run daily fluidics startup.
Optional: perform the flow cell clean.
c. Install the sort nozzle.
d. Run Cytometer Setup and Drop Delayi. Prepare a tube of B&D CS&T RUO beads by mixing 500 mL of PBS + 2 drops of beads.
ii. Vortex the mix of beads for at least 20 s before loading the tube and performing the
Optical configuration.
iii. Prepare a tube of Accudrop beads by mixing 500 mL of PBS + 1 drop of beads.
iv. Vortex the mix of beads for at least 20 s before loading the tube and performing the drop
delay.
e. Create protocol by setting forward scatter (FSC), side scatter (SSC), FITC, PE and Brilliant Vi-
olet421 Channels for measurement, for an appropriate gating strategy (Figure 4).
Note: Given the heterogeneous activation of Wnt pathway in CRC cells, it is always required
the analysis of untransduced cells, as Wnt negative control (see small inset in the third panel of
Figure 3). This will lead to a correct discrimination of Wntneg versus Wntpos (high and low,
defined as 10% highest versus 10% lowest positivity) CRC cells.
f. Run and record the experiment (Figure 5).
g. Export FCS files for data plotting and analysis.
10. Data analysis on FlowJo software.
Cell sorting + extreme limiting dilution analysis (ELDA)
Timing: 3–4 hours (cell sorting) + 3–4 weeks (ELDA)10 STAR Protocols 2, 100880, December 17, 2021
Figure 4. Cytotoxicity assay
Gating strategy for the analysis of cytotoxicity in TOP-GFP transduced CRC spheroids. Small inset represents the untransduced CRC cells, used as GFP/
RFP negative control.
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itor/differentiated cells) for downstream in vitro extreme limiting dilution assay (ELDA), in naı̈ve cells,
or following a specific anti-tumor treatment.
11. Harvest cellsa. Trypsinize and collect the cells in the corresponding tubes. Disassociate the clumps by pipet-
ting up and down with harsh pressure if cells grow in spheres or islands.
b. Label the cells with Brilliant Violet 421 Annexin V.
c. Filter the cells through a 70 mm cell strainer, to avoid the formation of cell clumps.
CRITICAL: To obtain reproducible results in terms of clonogenic potential of cancer cells itis crucial to not introduce any variation from cell collection to cell sorting. Be aware that the
cell culture conditions must be maintained the same for all the replicates (starting cell
viability of the cells, number of plated cells to be treated, volume of medium and time of
treatment), as well as the sample storage conditions between cell collection and cell sort-
ing. In this case, it is preferable to keep the samples at room temperature in a mix 1:1 of cell
culture medium: PBS, 2% FBS, 1 mM EDTA. FBS should be heat-inactivated before use by
heating it for 30 minutes at 56C with mixing, to inactivate complement proteins. It is
crucial not to keep the sample for too long in the tubes, while waiting for the sorting.
For this reason, it is suggested to prepare each sample in slightly advance compared to
the scheduled time of the sorting.12. Start up BD FACSMelody cell sorter (see point #9 for detailed information).
13. Load a previously saved experiment layout or create a new one.
14. Load the tube of cells that need to be analyzed/sorted and create the appropriate gating strat-
egy to analyze/sort the viable cells (SCC-A versus FSC-A: cells; FSC-H versus FSC-A: single cells;
BV421 versus FSC-A: alive cells) (see Figure 3).
15. In the ‘‘Set up’’ sort tab, select the format (plate), the volume and the sort mode (single cells).
16. Limited dilution sorting and cell plating.a. Prepare 96 well plates. Add 200 mL of complete culture medium in each well.
b. Change the recipient stand to 96 well plate holder.
c. Plan the 96 well plate as shown in Figure 6. Number in each well of the table indicates the cell
number to be seeded.
Note: When working with a highly clonogenic cell population, the setup of the 96 well plate
can be changed by plating only single cells in all the wells of the plate, to better define their
clonogenic potential. In this scenario, given the variable efficiency of the cell sorter (R60 % in
the best sorting conditions), it is preferable to use the U-Shaped-Bottom 96-well plate, as to
do so you will be able, just few minutes after the sorting, to check every single well, in order to
identify the well containing a single cell. Indeed, using the U-Shaped-Bottom microplate, theSTAR Protocols 2, 100880, December 17, 2021 11
Figure 5. Evaluation of cell death induction in Wnt+/- CRC cells
Analysis of cytotoxic effects in CSCs vs differentiated cancer cells in TOP-GFP transduced CRC spheroids.
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observation.
17. Start the sorting and record the events.
CRITICAL: During the sorting protocol, pay attention to the stability of the cell cloud to besorted (sometimes it can be affected by oscillations in laser intensity or fluidics change),
which could lead to the isolation of an unwanted cell population. Be aware that even small
variations in the room temperature where the instrument is located could affect the stabil-
ity of the selected parameters.Figure 6. Setup of FACS-based limiting dilution assay
96 well plate ELDA layout for the sorting of CRC cells to test their clonogenic potential. (Right panel) Phase contrast analysis of non clonogenic cell
versus positive clonogenic outgrowth of CRC cells growing in suspension, 7 days after cell sorting. Scale bar, 20 mm.
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Figure 7. Evaluation of CRC cells colony forming potential
Yellow wells represent those considered positive for the clonogenic outgrowth (acidification of the medium due to
cell metabolic activity), while pink-colored wells represent the negative clonogenic potential ones (no growth of
colonies, unaltered pH of the cell culture medium).
ll
OPEN ACCESSProtocol18. Place the 96 well plates back to incubator and culture it at 37C for 2 weeks, or longer, according
to the proliferation rate of each cell line.
19. Count the number of wells in which tumor sphere(s) grows out (Figure 7).
Note: When determining the outgrowth rate of the clonogenic cells, only count the well in
which tumor clones form instead of counting the colonies in the wells.
20. Calculate the clonogenic potential by ELDA online tool (http://bioinf.wehi.edu.au/software/
elda/) (Figure 8).
EXPECTED OUTCOMES
Lentiviral transduction of CRC cells will allow to monitor theWnt pathway activity in real-time by sim-
ply analyzing the Wnt-driven GFP expression by FACS. This protocol is mainly useful to discriminate
CRC stem cells, endowed with high Wnt pathway activity, and progenitors/differentiated cells that
are characterized by low activity of Wnt pathway. The evaluation of GFP expression by flow cytom-
etry gives the possibility to investigate the biological properties of these specific cell subsets (i.e.,
the clonogenic potential) (Figures 6, 7, and 8), as well as to study the cytotoxic activity of selected
anti-tumor compounds (Figures 4, 5, and 9).
QUANTIFICATION AND STATISTICAL ANALYSIS
To quantify the clonogenic potential following the ELDA online tool (http://bioinf.wehi.edu.au/
software/elda/), four parameters need to be entered as input to calculate the confidence intervals
defined as 1/ (stem cell frequency).
1. Dose: number of cells in each culture, herein specifically 1, 2, 4, 8, 16, 32, 64, and 128 for each
dilution.
2. Tested: number of cultures tested, herein specifically 24 tested wells for 1; 16 for 2 and 4; 8 for 8,
16, 32, 64, and 128 dilutions.
3. Response: number of positive cultures, herein, specifically refer to the number of wells in which it
has been observed a positive outgrowth of the colony.STAR Protocols 2, 100880, December 17, 2021 13
Figure 8. CRC cells clonogenic potential calculation
Comparison of clonogenicity of bulk versus TOP-GFPlow/high CRC cells. The confidence intervals for 1/ (stem cell
frequency) are calculated by ELDA online tool (left panel) and the percentage of clonogenic cells are plotted (right
panel).
ll
OPEN ACCESS Protocol4. Group (optional): label for the population group to which cells belong (i.e., untreated versus
treated) (see Figure 9).
LIMITATIONS
Although most tumor cells possess sufficient levels of Wnt pathway activations to visualize GFP
expression (in particular in cancer cells bearing APC, BRAF or KRAS mutations), in some cases this
may not occur, making it impossible to isolate and study specific tumor populations (CSCs, progen-
itors and differentiated cells).
TROUBLESHOOTING
Problem 1
Absence of GFP expression following TOP-GFP transduction of CRC cells (step 3a).
Potential solution
Even if it is likely a rare event, it is possible to notice the absence of GFP expression in CRC cells upon
transduction with TOP-GFP lentiviral vector (Figure 10). This can be a serious issue if the lentiviral
plasmid without the constitutive expression of mCherry RFP is used (cat. #35489 and #35490, Addg-
ene), because the absence of GFP could be read as a failure in cell transduction, thus leading to a
serious waste of time. In this case, the use of mCherry RFP bearing lentiviral plasmid is highly sug-
gested (cat. #35491 and #35492, Addgene). Moreover, it would be useful to first transiently transfect
the CRC cells to evaluate if their Wnt pathway activity is enough to drive the expression of detectable
levels of GFP, before proceeding with CRC stable lentiviral transduction.
Problem 2
Absence of violet laser/filter in the flow cytometer/sorter (step 9).
Potential solution
In this case it is highly recommended the use of a Wnt-reporter plasmid without the constitutive
expression of RFP (Addgene, cat. #35489; #35490), thus making it possible the use of a kit of
apoptosis with a dye in the red fluorescent channel (i.e., CaspGLO Red Active Caspase Staining
Kit, BioVision, cat. #K190 or #K193). Be aware that in this scenario, as mentioned before, the nega-
tive expression of GFP after cancer cell transduction, could be due to a non-optimal transduction, or
to the low activity of the Wnt pathway, thus making difficult the interpretation of the results.14 STAR Protocols 2, 100880, December 17, 2021
Figure 9. Online ELDA tool set-up




Evaluation of cytotoxic effects of compounds affecting Wnt pathway activity (steps 9 and 10).Potential solution
If the compound(s) used for evaluation of cytotoxicity in Wnthigh versus Wntlow CRC cells is known to
affect the Wnt pathway activity (or when no information has been previously reported), it would be
crucial to perform a cell sorting to isolate the two cell subsets before to perform the cytotoxic assay.
This experimental setting will allow to evaluate at the same time the induction of cell death and the
possible reprogramming in terms of Wnt pathway activity (Wnthigh to Wntlow, and vice versa).Problem 4
No evidence of cytotoxicity of selected anti-tumor drugs (steps 9 and 10).Potential solution
To note, following cell sorting, it is common to observe the induction of cell cycle arrest (G0-G1
phase) in CRC cells for 12–24 h, due to the stress of cell sorting procedure. In this scenario, that
need to be evaluated in advance, it is crucial to wait 24 h following cell sorting before starting the
cytotoxic assay (in particular when using cytotoxic drugs that specifically target proliferating cells).Problem 5
Excess of cell culture medium evaporation during clonogenic outgrowth (step 18).Potential solution
Given the low amount of medium in each well of the 96 well plate used for clonogenic assay (about
100–120 mL), and the long-term incubation of the plated cells (15–21 days to observe a clonogenic
outgrowth), it is commonly observed a decrease in cell culture medium due to evaporation, which
could lead to cell sufferance and compromise the clonogenic outgrowth of cancer cells. If the sorted
cells are grown in basal medium, it is possible to refresh the medium in each well over time (adding
20–50 mL once a week). Otherwise, if the cells are plated in cell culture medium containing a specificSTAR Protocols 2, 100880, December 17, 2021 15
Figure 10. Monitoring the transduction of CRC cells with Wnt reporter construct
CRC spheroids efficiently transduced with Wnt reporter gene (with constitutive RFP expression), lacking the expression of Wnt-driven GFP. Scale bar,
400 mm.
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OPEN ACCESS Protocolanti-tumor drug, or cells are grown in suspension, to avoid manipulating the wells (this will introduce
a variability in the assay), it is highly recommended to wrap the plate with a single thin layer of
parafilm.Problem 6
No difference in clonogenic potential between Wnthigh and Wntlow cell subsets (steps 19 and 20).Potential solution
We have already experienced the possibility to not find any difference in the clonogenic potential of
Wnthigh andWntlow CRC cells. In this scenario, researchers should be aware that the mutational back-
ground, in particular the presence of activating mutations occurring in Wnt pathway components
(i.e., b-catenin mutation in HCT-116 cell line), could affect CRC cells’ clonogenic potential. Thus,
this biological condition leads to a boost in basal Wnt pathway activity, thus making it impossible
to notice any difference betweenWnthigh andWntlow CRC cells in terms of clonogenic potential (Ver-
meulen et al., 2010).Problem 7
Sorted cells show no clonogenic potential (steps 19 and 20).Potential solution
It is important to highlight that some CRC cells strongly suffer from the cell sorting procedure, thus
making it difficult to perform the clonogenic assay due to the high induction of cell death. To avoid
facing this issue after CRC cell transduction, it would be crucial to select the right cell lines to work
with, by performing a preliminary screening of cell lines not suffering from cell sorting protocol.RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be ful-
filled by the lead contact, Giorgio Stassi (giorgio.stassi@unipa.it).Materials availability
This study did not generate new unique reagents.Data and code availability
This study did not generate/analyze data sets/code.16 STAR Protocols 2, 100880, December 17, 2021
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